{"version":"1.0","type":"link","title":"Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology.","author_name":"Zou M 외","author_url":"https://prs-insight.online/author/Zou%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/109755","thumbnail_width":1200,"thumbnail_height":630}